BioCentury
ARTICLE | Clinical News

PTVG-HP: Phase I/II started

September 28, 2015 7:00 AM UTC

Madison Vaccines began an open-label, U.S. Phase I/II trial to evaluate intradermal MVI-816 every 2 weeks for 6 doses with IV Keytruda pembrolizumab in about 32 patients. Patients will receive Keytru...